Streetbeat News

AEMD

Aethlon Medical, Inc.

https://www.aethlonmedical.com

Industry

Medical - Devices

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.

Open

0.39

Mkt cap

5.6M

Volume

271K

High

0.42

P/E Ratio

-0.14

52-wk high

2.35

Low

0.38

Div yield

N/A

52-wk low

0.24

Aethlon Medical's stock is rising following ethics committee approval for its Hemopurifier cancer treatment. Additionally, the European Commission has recommended extending the smallpox and mpox vaccine to adolescents.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 11:50 am

The European Medicines Agency (EMA) has recommended extending the use of the Imvanex vaccine to adolescents aged 12-17. This decision is based on a study showing similar immune responses in adolescents and adults. The vaccine, already authorized for adults in the EU, is crucial for addressing the mpox outbreak in the Democratic Republic of the Congo and other regions. The EMA's recommendation supports WHO's prequalification process, facilitating broader access to the vaccine.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 3:41 pm

Aethlon Medical has received ethics committee approval to conduct a Hemopurifier cancer trial in India. The trial targets patients with solid tumors unresponsive to anti-PD-1 therapy.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 12:04 pm

The US government is committed to controlling the Mpox outbreak, which may impact companies involved in vaccine development and distribution.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:49 pm

Aethlon Medical has activated the Royal Adelaide Hospital to begin patient screening and enrollment for its Hemopurifier cancer trial. This trial focuses on patients with solid tumors not responding to anti-PD-1 antibodies.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:33 pm

Morocco has reported its first case of Mpox, as per Reuters citing state TV. This development could impact companies involved in vaccine and treatment development for Mpox.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 4:30 pm

The CDC reports no cases of Clade I Mpox in the U.S. as of September 6, while Clade II Mpox continues to circulate at low levels.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 7:18 pm

The U.S. is preparing for the potential arrival of a more severe strain of mpox, clade 1, which has caused significant cases and deaths in Africa. The government is enhancing surveillance and testing, and the Jynneos vaccine is available for high-risk groups. Efforts are underway to develop new treatments, although current options like TPOXX are ineffective against clade 1.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 6:24 pm

The European Commission has delivered 100,000 mpox vaccine doses to the Democratic Republic of Congo, with more to follow. This is part of a larger EU initiative to combat the mpox outbreak in Africa, involving donations from multiple EU countries and coordination with the Africa CDC.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 2:19 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.